Navigation Links
Stop smoking and reduce weight

7 weeks. No medication of any kind was provided.One year after treatment, 21 percent of the women who received therapy to allay their concerns about weight gain had completely quit smoking (with no relapses), compared to 13 percent of the weight control group, and 9 percent of the standard therapy group.

The women in the study did gain weight after quitting smoking. Those in the weight control group initially had the smallest weight gain, as expected, but as time went on, their weight gain was comparable to women in the standard therapy group. Surprisingly, the women in the group receiving therapy to allay their concerns about weight gain fared the best in terms of preventing weight gain. At one-year follow-up after treatment, they had gained less weight than women in either the weight control or the standard therapy groups. Women in the weight counseling group gained, on average, 5.5 pounds, while women in the weight control and the standard therapy groups gained on average 11.9 pounds and 16.9 pounds, respectively.

Dr. Perkins says these results indicate that "the critical factor influencing smoking relapse in women concerned about gaining weight may be the women's over-concern about weight gain, rather than the experience of weight gain itself."


'"/>




Page: 1 2

Related medicine news :

1. Vaccine to quit smoking?
2. ZYBAN, The smoking cessation drug marked for its adverse reactions
3. A boost to quit smoking
4. Quitting smoking stops lung decline
5. Passive smoking affects respiratory system
6. Teens listen to parents about smoking
7. Teen smoking declines
8. Cancer patients pursue smoking inspite of risks
9. A new herbal therapy to quit smoking
10. Watching television linked to smoking
11. Quit smoking after cancer diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Stop smoking and reduce weight

Other Medicine News:Health News:Survivors of 1918 Flu Pandemic Immune 90 Years Later 2Health News:Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxin Toxicity 2Health News:Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxin Toxicity 3Health News:Direct From Beijing, 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Women's Cancer Awareness Special, Frosted Pink With A Twist 2Health News:Direct From Beijing, 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Women's Cancer Awareness Special, Frosted Pink With A Twist 3Health News:Experiments could lead to new treatments for neuroblastoma 2Health News:Experiments could lead to new treatments for neuroblastoma 3Health News:HDSA Applauds Announcement of the First Therapy to be Approved for the Specific Treatment of a Symptom of Huntington's Disease 2Health News:Study Probes Internet Health-Related Search Patterns 2
Breaking Medicine Technology:BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 1Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 2Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 3American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 1American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 1Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 3
Other Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4